In a strategically significant move announced on November 14, 2025, Merck & Co., Inc. has revealed definitive plans to acquire Cidara Therapeutics, a biotechnology company renowned for its innovative drug-Fc conjugate (DFC) therapeutics, in a transaction valued at approximately $9.2 billion. This acquisition reflects Merck’s ongoing commitment to reinforce its scientific-driven business development strategy, targeting portfolio diversification and reinforcing its pipeline strength notably in the respiratory and infectious disease areas.

The centerpiece of the acquisition is Cidara’s investigational antiviral agent CD388, a long-acting, strain-agnostic therapeutic designed to prevent influenza A and B in individuals who are at a heightened risk of complications from flu infections. CD388 utilizes a propriety small molecule neuraminidase inhibitor stably conjugated to an Fc fragment of a human antibody. This design aims to offer a universal approach to influenza prevention, supplementing current vaccine and antiviral strategies, particularly for immunocompromised patients, older adults, and those with chronic diseases who are less responsive to conventional interventions.

The drug is currently in Phase 3 clinical trials under the ANCHOR study (NCT07159763), focused on adults and adolescents at higher risk of influenza complications. Supported by compelling Phase 2b data from the NAVIGATE study (NCT06609460), CD388 has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. Food and Drug Administration. The NAVIGATE study achieved all key efficacy endpoints, positioning CD388 as a potentially first-in-class option for proactive, season-independent flu protection.

Merck’s CEO, Robert M. Davis, emphasized the acquisition’s anticipated value creation, both in generating shareholder returns and delivering public health impact. He stated confidence in the Cidara team’s remarkable progress and the innovation embodied within CD388. The advanced nature and unique profile of CD388 will allow Merck to build on recent advancements in universal antiviral approaches and complement its existing respiratory product portfolio. The company’s scale and regulatory expertise are expected to accelerate development and expand global access to the asset, should regulatory approvals be secured.

For Cidara, the acquisition marks a transformational milestone. CEO Jeffrey Stein, Ph.D., highlighted the opportunity to redefine influenza prevention, citing positive NAVIGATE study results and Merck’s capacity for global development, commercialization, and regulatory support. Merck and Cidara’s respective Boards of Directors have approved the acquisition, which is now subject to Cidara shareholder acceptance. Full merger agreement details and related documentation will be filed with the SEC for public reference, ensuring comprehensive oversight and transparency throughout the process.

This deal is also noteworthy for both clinical outsourcing and manufacturing partners. The multicentric ANCHOR study, ongoing in the U.S. and UK, involves extensive engagement with CROs and specialized service providers. CD388’s complex conjugation chemistry and biologic manufacturing requirements could drive facility upgrades, automation investments, analytical equipment deployment, and regulatory scrutiny related to combination biologics and ADC-style pipeline assets.

Further strategic implications arise for procurement and supply chain professionals as Merck integrates Cidara’s platform. The acquisition is expected to prompt shifts in sourcing for raw materials, reagents, and cold chain logistics necessary for CD388’s stability and safety profile. Furthermore, the pending regulatory milestones—especially regarding the FDA's Breakthrough and Fast Track pathways—will likely affect the timeline for commercialization, potential for early access programs, and coordination with manufacturing and distribution partners.

A Merck investor call to discuss transaction details is scheduled for Monday, November 17, 2025, and further updates on clinical, manufacturing, and regulatory strategy are anticipated. This acquisition exemplifies the B2B pharmaceutical sector’s robust M&A environment, targeting assets in advanced therapeutic areas critical to public health preparedness while leveraging external innovation to maintain pipeline and competitive advantage in the antiviral space.